Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biocytogen Out-Licenses Global Rights for mAb Candidates to Hansoh

publication date: Jan 3, 2023

Biocytogen Pharma (Beijing) out-licensed fully human antibody molecules to Jiangsu Hansoh Pharma for a target designated by Hansoh. Hansoh will have global rights to the molecules, which were discovered and developed on Biocytogen’s RenMiceTM platforms. Biocytogen will receive an upfront payment plus milestones of up to tens of millions of Chinese yuan, along with single-digit royalties on net sales, though no specific details were disclosed. Hansoh is a large China pharma that is actively making deals to expand its portfolio of novel drug offerings. More details....

Stock Symbols: (HK: 02315) (HK: 3692)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital